PDCD1 and neoplasm: However, the most effective regimen in terms of tumor volume was the treatment with AdV-D24-ICOSL-CD40L in combination with anti PD-1 antibody on day 6 and day 21 (Figure 5C,D) thus indicating the most significant antitumor activity compared to other groups.